NUVB

Nuvation Bio Inc

4.70

Nov 03 • 9:52 AM ET +0.11 (2.29%)

Healthcare Biotechnology USA Small NYSE

Peers: SNDX CGEM ORIC VSTM RCUS TNGX BMY BDTX IOVA PFE

| Held by: VTI IWM VXF IWO IBB VTWO XPH SCHA FYC IHE

Index	RUT
Market Cap	1.65B
Enterprise Value	1.41B
Income	-149.83M
Sales	169.90M
Book/sh	0.73
Cash/sh	1.88
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	298
IPO	Aug 26, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	9.73
P/B	6.47
P/C	2.50
P/FCF	-
EV/EBITDA	-
EV/Sales	8.29
Quick Ratio	8.14
Current Ratio	8.37
Debt/Eq	1.64
LT Debt/Eq	1.56
Option/Short	Yes / Yes

EPS (ttm)	-0.44
EPS next Y	-0.21
EPS next Q	-0.12
EPS this Y	32.79%
EPS next Y	47.81%
EPS next 5Y	-
EPS past 3/5Y	-7.61% -7.00%
Sales past 3/5Y	- -
EPS Y/Y TTM	30.89%
Sales Y/Y TTM	1083.56%
EPS Q/Q	-4.04%
Sales Q/Q	555.64%
Earnings	Nov 04 AMC
EPS/Sales Surpr.	-27.03% 17.24%

Insider Own	28.44%
Insider Trans	-0.31%
Inst Own	56.25%
Inst Trans	5.86%
ROA	-21.53%
ROE	-47.81%
ROIC	-23.07%
Gross Margin	86.91%
Oper. Margin	-81.00%
Profit Margin	-88.19%
SMA20	-0.26%
SMA50	-15.34%
SMA200	-12.79%
Trades

Shs Outstand	348.82M
Shs Float	251.98M
Short Float	25.09%
Short Ratio	11.87
Short Interest	63.22M
52W High	9.75 -51.85%
52W Low	3.92 19.77%
Volatility	4.71% 5.08%
ATR (14)	0.24
RSI (14)	41.88
Beta	1.73
Rel Volume	0.80
Avg Volume	5.33M
Volume	439,662

Perf Week	3.19%
Perf Month	-5.15%
Perf Quarter	-26.30%
Perf Half Y	-2.80%
Perf YTD	-47.60%
Perf Year	-9.19%
Perf 3Y	247.78%
Perf 5Y	-50.47%
Perf 10Y	-
Recom	1.15
Target Price	13.00
Prev Close	4.59
Price	4.70
Change %	2.29%

Consensus

Strong Buy

Avg. Price Target

$13.00

Implied Upside

+176.9%

Analysts13incl. previous ratings

Rating Distribution12 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 30, 2026	Initiated	CCitigroup	Buy	$12	+155.6%
Aug 21, 2026	Initiated	CCantor Fitzgerald	Overweight
Aug 18, 2026	Initiated	JJP Morgan	Overweight	$13	+176.9%
Nov 24, 2025	Initiated	TTruist	Buy
Nov 19, 2025	Initiated	RB. Riley Securities	Buy	$12	+155.6%
Sep 30, 2025	Initiated	JJefferies	Buy	$10	+113.0%
Apr 23, 2025	Initiated	CCitizens JMP	Mkt Outperform	$6	+27.8%
Mar 27, 2024	Upgrade	JJefferies	Hold → Buy	$1.40 → $10	+113.0%
Mar 26, 2024	Upgrade	BBTIG Research	Neutral → Buy	$5	+6.5%
Jan 06, 2023	Downgrade	JJefferies	Buy → Hold	$5 → $2	-57.4%
Aug 02, 2022	Downgrade	BBTIG Research	Buy → Neutral
Aug 02, 2022	Downgrade	BBMO Capital Markets	Outperform → Market Perform	$8 → $2.50	-46.8%
May 04, 2022	Initiated	HH.C. Wainwright	Buy	$14	+198.2%
Oct 15, 2021	Resumed	BBTIG Research	Buy	$16	+240.8%
Apr 06, 2021	Initiated	RRBC Capital Mkts	Outperform	$15	+219.5%
Mar 08, 2021	Initiated	WWedbush	Outperform	$20	+326.0%
Mar 08, 2021	Initiated	JJefferies	Buy	$20	+326.0%
Mar 08, 2021	Initiated	CCowen	Outperform
Mar 08, 2021	Initiated	BBTIG Research	Buy	$16	+240.8%
Mar 08, 2021	Initiated	BBMO Capital Markets	Outperform	$16	+240.8%

Nov-02-26 08:00AM	Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting (PR Newswire)
Oct-29-26 08:00AM	Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries (PR Newswire)
Oct-27-26 06:43PM	Nuvation Bio's First-Line Ibtrozi Bet Faces A Skeptical Market After A 25% Slide (Earnings Whispers)
Oct-21-26 04:05PM	Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026 (PR Newswire)
Sep-17-26 07:30AM	Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in TKI-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer (PR Newswire) +5.02%
08:00AM	Loading…
Sep-15-26 08:00AM	Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer (PR Newswire)
Sep-02-26 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-20-26 08:00AM	Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma (PR Newswire) -5.92%
Aug-06-26 07:30AM	Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
Aug-04-26 08:00AM	Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses (PR Newswire)
Jul-22-26 04:05PM	Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 (PR Newswire)
Jul-20-26 01:05PM	NUVB Stock Is Soaring Today Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug (Stocktwits) +7.93%
08:00AM	Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma (PR Newswire)
Jul-06-26 05:09PM	Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering (PR Newswire)
Jul-01-26 05:05AM	Doctor-turned-dealmaker reveals his M&A playbook (Pharma Voice)
08:00AM	Loading…
Jun-29-26 08:00AM	Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom (PR Newswire)
Jun-25-26 11:58PM	Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes (PR Newswire) -10.06%
10:42AM	Why Is NUVB Stock Falling Today? (Stocktwits)
07:00AM	Nuvation Bio Announces Proposed Convertible Senior Notes Offering (PR Newswire)
May-27-26 04:05PM	Nuvation Bio to Present at the Jefferies Global Healthcare Conference (PR Newswire)
08:00AM	Nuvation Bio to Present New Quality-of-Life Data for IBTROZI (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting (PR Newswire)
May-13-26 04:05PM	Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI for ROS1-Positive Non-Small Cell Lung Cancer (PR Newswire)
May-06-26 08:00AM	Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer (PR Newswire)
May-05-26 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (PR Newswire) +9.52%
May-04-26 04:10PM	Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
May-01-26 09:18AM	Nuvation Bio Inc (NUVB) Q1 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
Apr-27-26 08:00AM	Nuvation Bio Announces National Comprehensive Cancer Network Adds Taletrectinib (IBTROZI) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers (PR Newswire) -6.75%
Apr-21-26 06:00PM	Nuvation Bio Announces IBTROZI (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026 (PR Newswire)
Apr-20-26 04:05PM	Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 (PR Newswire)
Apr-01-26 08:00AM	Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo (PR Newswire) +5.13%
04:05PM	Loading…
Mar-26-26 04:05PM	Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency (PR Newswire)
Mar-17-26 04:35PM	Nuvation Bio to Present Pivotal IBTROZI (Taletrectinib) Data in TKI-Naive and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026 (PR Newswire)
Mar-04-26 11:40AM	Nuvation Bio (NUVB) Generates $62.9M Annual Revenue Following Successful Erozi Launch (Insider Monkey) +8.72%
Mar-03-26 12:01AM	Nuvation Bio Inc (NUVB) Q4 2025 Earnings Call Highlights: Strong Market Acceptance of Erozi ... (GuruFocus.com) -25.34%
Mar-02-26 08:10PM	Nuvation Bio Q4 Earnings Call Highlights (MarketBeat)
05:35PM	Nuvation Bio Inc. (NUVB) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (PR Newswire)
02:56AM	Nuvation Bio Inc. (NUVB) Amends Protocol on Safusidenib Trials in Astrocytoma (Insider Monkey)
Feb-27-26 07:17AM	Nuvation Bio Inc (NUVB) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-26-26 11:53PM	Where is Nuvation Bio Inc. (NUVB) Headed According to Wall Street Analysts? (Insider Monkey)
10:00AM	Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-25-26 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-17-26 04:05PM	Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026 (PR Newswire)
11:17AM	New Treatment Modalities Are Reaching Cancers That Resisted Everything Else (PR Newswire)
Feb-09-26 08:00AM	Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma (Business Wire)
Jan-30-26 09:47AM	Turist Financial Remains a Buy on Nuvation Bio (NUVB) (Insider Monkey)
12:24AM	Truist Highlights Nuvation Bio's (NUVB) Ibtrozi's Robust Market Uptake and Lead Over Competitors (Insider Monkey)
Jan-28-26 08:28AM	Nuvation Bio price target raised to $13 from $11 at Truist (TipRanks) -5.53%
Jan-20-26 04:59AM	Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations (Insider Monkey)
Jan-19-26 08:01AM	Here's What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) (Insider Monkey)
Jan-15-26 11:35AM	Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib (Insider Monkey)
Jan-13-26 09:35AM	Down 24% in 4 Weeks, Here's Why Nuvation Bio (NUVB) Looks Ripe for a Turnaround (Zacks)
Jan-12-26 08:00AM	Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference (Business Wire) -19.65%
07:30AM	Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan (Business Wire)
Jan-06-26 04:05PM	Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-05-26 09:55AM	Wall Street Analysts Think Nuvation Bio (NUVB) Could Surge 32.05%: Read This Before Placing a Bet (Zacks)
Dec-19-25 09:55AM	Wall Street Analysts Believe Nuvation Bio (NUVB) Could Rally 25.14%: Here's is How to Trade (Zacks) +5.01%
Dec-15-25 12:00PM	Nuvation Bio (NUVB) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-06-25 10:40PM	Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List (PR Newswire)
Dec-04-25 12:55PM	Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result (Insider Monkey)
Dec-03-25 08:00AM	Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology (Business Wire) +12.05%
Nov-26-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
Nov-20-25 06:27AM	Nuvation Bio (NUVB) Jumps to 3-Year High on Bullish Coverage (Insider Monkey)
Nov-18-25 06:17AM	Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress (Insider Monkey)
Nov-07-25 09:34PM	Is Nuvation Bio (NUVB) One of the Best American Penny Stocks to Buy? (Insider Monkey) -5.78%
Nov-04-25 12:01AM	Nuvation Bio Inc (NUVB) Q3 2025 Earnings Call Highlights: Strong IBTROZI Launch and Robust ... (GuruFocus.com) -6.58%
Nov-03-25 05:55PM	Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Oct-31-25 09:22AM	Nuvation Bio Inc (NUVB) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-30-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
Oct-29-25 05:25PM	MiMedx (MDXG) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-23-25 07:30AM	Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma (Business Wire) +5.78%
Oct-20-25 04:05PM	Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025 (Business Wire) +8.50% +13.78%
Oct-08-25 01:02PM	Nuvation Bio Inc. (NUVB): A Bull Case Theory (Insider Monkey)
08:55AM	NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street (PR Newswire)
Sep-30-25 11:33AM	Why Nuvation Bio Stock Is Skyrocketing Today (Motley Fool) +14.91%
07:30AM	Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer (Business Wire)
Sep-19-25 07:30AM	Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Sep-07-25 06:00AM	Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer (Business Wire)
Aug-27-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
09:55AM	Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Aug-25-25 11:56PM	H.C. Wainwright Reiterates a Buy Rating on Nuvation Bio (NUVB) (Insider Monkey)
Aug-07-25 08:45AM	Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:30AM	Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Aug-06-25 05:15PM	Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates (Zacks)
Aug-05-25 08:00AM	Nuvation Bio To Present New Data on IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses (Business Wire)
Aug-01-25 06:46AM	Nuvation Bio (NUVB)'s Taletrectinib Selected as Preferred Agent for Cancer Treatment (Insider Monkey) -5.51%
Jul-24-25 04:05PM	Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 (Business Wire)
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire)
Jul-09-25 12:00PM	All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy (Zacks) +15.61%
Jun-29-25 03:00AM	Two Beaten-Down Biotech Stocks See Big Insider Buys (Barrons.com)
Jun-24-25 05:33PM	RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating (Insider Monkey) -8.29%
07:00AM	Nuvation Bio Announces National Comprehensive Cancer Network Adds Taletrectinib (IBTROZI) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers (Business Wire)
Jun-20-25 02:25PM	Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now? (Barchart) +10.06%
Jun-11-25 01:20PM	U.S. Food and Drug Administration Approves Nuvation Bios IBTROZI (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer (Business Wire) -13.04%
12:52AM	FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche (BioPharma Dive)
May-21-25 04:05PM	Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting (Business Wire) -6.45% +10.84%
May-13-25 04:05PM	Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025 (Business Wire)
May-12-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 01:00PM	Nuvation Bio Inc (NUVB) Q1 2025 Earnings Call Highlights: Promising Developments and Strategic Moves (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Aug 19 '26	Option Exercise	1.87	100,000	187,000	100,000	Aug 21 04:49 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Aug 19 '26	Sale	7.09	100,000	709,240	0	Aug 21 04:49 PM
GARY HATTERSLEY	Officer	Aug 19 '26	Proposed Sale	6.96	100,000	696,000		Aug 19 04:30 PM
Sauvage Philippe	Chief Financial Officer	Jul 15 '26	Option Exercise	2.17	40,000	86,800	54,131	Jul 17 06:27 PM
Markel Stacy	CHIEF PEOPLE OFFICER	Jun 23 '26	Option Exercise	1.83	125,000	229,249	157,591	Jun 24 07:09 PM
Markel Stacy	CHIEF PEOPLE OFFICER	Jun 23 '26	Sale	6.03	125,000	753,188	32,591	Jun 24 07:09 PM
Wentworth Kerry	CHIEF REGULATORY OFFICER	Jun 23 '26	Option Exercise	2.93	63,000	184,590	116,000	Jun 24 07:07 PM
Wentworth Kerry	CHIEF REGULATORY OFFICER	Jun 23 '26	Sale	6.02	63,000	379,191	53,000	Jun 24 07:07 PM
Sauvage Philippe	Chief Financial Officer	Jun 23 '26	Option Exercise	2.17	47,668	103,440	60,341	Jun 24 07:07 PM
Sauvage Philippe	Chief Financial Officer	Jun 23 '26	Sale	6.01	47,668	286,370	12,673	Jun 24 07:07 PM
STACY MARKEL	Officer	Jun 23 '26	Proposed Sale	5.76	125,000	720,000		Jun 23 04:28 PM
KERRY WENTWORTH	Officer	Jun 23 '26	Proposed Sale	5.76	63,000	362,880		Jun 23 04:28 PM
PHILIPPE SAUVAGE	Officer	Jun 23 '26	Proposed Sale	5.76	47,668	274,568		Jun 23 04:27 PM
Mashal Robert	Director	Jun 09 '26	Buy	4.73	25,000	118,250	225,000	Jun 11 08:02 PM
Wentworth Kerry	CHIEF REGULATORY OFFICER	Apr 17 '26	Option Exercise	2.93	36,750	107,678	89,750	Apr 21 04:35 PM
Wentworth Kerry	CHIEF REGULATORY OFFICER	Apr 17 '26	Sale	5.01	36,750	184,279	53,000	Apr 21 04:35 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Apr 17 '26	Option Exercise	1.94	50,000	97,000	68,000	Apr 21 04:34 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Apr 17 '26	Sale	5.02	50,000	251,000	18,000	Apr 21 04:34 PM
DONGFANG LIU	Officer	Apr 17 '26	Proposed Sale	4.81	50,000	240,500		Apr 17 04:39 PM
KERRY WENTWORTH	Officer	Apr 17 '26	Proposed Sale	4.81	36,750	176,768		Apr 17 04:39 PM
Wentworth Kerry	CHIEF REGULATORY OFFICER	Apr 06 '26	Option Exercise	1.91	200,000	381,000	253,000	Apr 08 04:23 PM
Wentworth Kerry	CHIEF REGULATORY OFFICER	Apr 06 '26	Sale	4.52	200,000	903,560	53,000	Apr 08 04:23 PM
KERRY WENTWORTH	Officer	Apr 06 '26	Proposed Sale	4.41	200,000	882,000		Apr 06 04:24 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Dec 01 '25	Option Exercise	2.93	150,000	439,500	168,000	Dec 03 05:02 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Dec 01 '25	Sale	7.82	150,000	1,173,255	18,000	Dec 03 05:02 PM
DONGFANG LIU	Officer	Dec 01 '25	Proposed Sale	7.82	150,000	1,173,255		Dec 01 04:51 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 25 '25	Option Exercise	3.61	10,000	36,100	28,000	Nov 26 05:55 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 26 '25	Option Exercise	3.61	10,000	36,100	28,000	Nov 26 05:55 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 26 '25	Sale	8.00	10,000	80,000	18,000	Nov 26 05:55 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 25 '25	Sale	7.50	10,000	75,000	18,000	Nov 26 05:55 PM
DONGFANG LIU	Officer	Nov 26 '25	Proposed Sale	8.00	10,000	80,000		Nov 26 04:33 PM
DONGFANG LIU	Officer	Nov 25 '25	Proposed Sale	7.50	10,000	75,000		Nov 25 04:23 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Nov 20 '25	Option Exercise	1.90	369,051	702,149	300,000	Nov 24 04:09 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Nov 20 '25	Sale	7.23	369,051	2,667,132	0	Nov 24 04:09 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 20 '25	Option Exercise	1.87	20,000	37,400	38,000	Nov 24 04:08 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 20 '25	Sale	7.00	20,000	140,074	18,000	Nov 24 04:08 PM
Hanley David C.	CHIEF TECHNICAL OPERATIONS	Nov 19 '25	Option Exercise	1.87	200,000	374,000	224,000	Nov 21 04:05 PM
Hanley David C.	CHIEF TECHNICAL OPERATIONS	Nov 19 '25	Sale	7.14	200,000	1,427,680	24,000	Nov 21 04:05 PM
GARY HATTERSLEY	Officer	Nov 20 '25	Proposed Sale	7.23	369,051	2,667,132		Nov 20 04:12 PM
DONGFANG LIU	Officer	Nov 20 '25	Proposed Sale	7.00	20,000	140,074		Nov 20 04:07 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 19 '25	Option Exercise	1.87	15,000	28,050	30,000	Nov 19 04:47 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 17 '25	Option Exercise	1.87	15,000	28,050	30,000	Nov 19 04:47 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 19 '25	Sale	5.10	15,000	76,552	18,000	Nov 19 04:47 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 17 '25	Sale	4.76	15,000	71,475	15,000	Nov 19 04:47 PM
DONGFANG LIU	Officer	Nov 19 '25	Proposed Sale	5.10	15,000	76,552		Nov 19 04:18 PM
DAVID HANLEY	Officer	Nov 19 '25	Proposed Sale	7.14	200,000	1,427,680		Nov 19 04:09 PM
DONGFANG LIU	Officer	Nov 17 '25	Proposed Sale	4.76	15,000	71,475		Nov 17 04:12 PM

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

FounderDr. David T. Hung M.D.

CFO & Principal Financial OfficerMr. Philippe Pierre Sauvage

Chief Scientific OfficerDr. Gary Hattersley Ph.D.

VP of Finance and Principal Accounting & Financial OfficerMr. Moses Makunje CPA

Chief Technical Operations OfficerDr. David C. Hanley Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NUVB

Nuvation Bio Inc

Upgrade your Finviz experience